Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
In development
Reference number: GID-TA10747
Expected publication date: TBC
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in late October 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-January 2024.